News25/Ratings12
Price$117.74+45.78 (+63.63%)
2026-07-162026-10-16
News · 26 weeks56+67%
2026-04-192026-10-11
Mix2590d
- Insider10(40%)
- Other9(36%)
- Earnings2(8%)
- SEC Filings2(8%)
- Analyst2(8%)
Latest news
25 items- INSIDERSEC Form 4 filed by GRAIL Inc.4 - GRAIL, Inc. (0001699031) (Issuer)
- INSIDERSEC Form 4 filed by GRAIL Inc.4 - GRAIL, Inc. (0001699031) (Issuer)
- INSIDERSEC Form 4 filed by GRAIL Inc.4 - GRAIL, Inc. (0001699031) (Issuer)
- INSIDERSEC Form 4 filed by GRAIL Inc.4 - GRAIL, Inc. (0001699031) (Issuer)
- INSIDERSEC Form 4 filed by GRAIL Inc.4 - GRAIL, Inc. (0001699031) (Issuer)
- INSIDERSEC Form 4 filed by GRAIL Inc.4 - GRAIL, Inc. (0001699031) (Issuer)
- PRGRAIL to Present New Data From NHS-Galleri and PATHFINDER 2 at EDCC and ESMO Congress 2026GRAIL to Present Six Abstracts at the Early Detection of Cancer Conference (EDCC) Spanning Clinical Performance, Health Equity, and Real-World Implementation of Multi-Cancer Early DetectionGRAIL to Present Two Abstracts at the European Society for Medical Oncology (ESMO) Congress, Across the Cancer Diagnostic Journey and Real-World EvidenceSUNNYVALE, Calif., Oct. 5, 2026 /PRNewswire/ -- GRAIL, Inc. (NASDAQ:GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, will present additional data from both the NHS-Galleri trial and the PATHFINDER 2 study further evaluating the Galleri® multi-cancer early detection (MCED) test at the Early Detection of Cancer Confer
- PRFDA Advisory Committee Votes In Favor of Approval of GRAIL's Galleri® Multi-Cancer Early Detection TestSUNNYVALE, Calif., Sept. 23, 2026 /PRNewswire/ -- GRAIL, Inc., a healthcare company whose mission is to detect cancer early when it can be cured, today announced a favorable vote from the Molecular and Clinical Genetics Devices Panel of the Medical Devices Advisory Committee (the Committee) of the U.S. Food and Drug Administration (FDA) for the approval of the Premarket Approval (PMA) application of the Galleri® multi-cancer early detection test (MCED). In three separate votes, the 10 voting members of the Committee considered Galleri's safety, effectiveness and overall benefit-risk profile for screening for the early detection
- INSIDERChief Financial Officer Freidin Aaron sold $382,679 worth of shares (4,100 units at $93.34) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 248,983 units (SEC Form 4)4 - GRAIL, Inc. (0001699031) (Issuer)
- INSIDERChief Executive Officer Ofman Joshua J. exercised 26,452 shares at a strike of $14.00 and sold $6,006,378 worth of shares (61,452 units at $97.74) as part of a pre-agreed trading plan, decreasing direct ownership by 9% to 362,271 units (SEC Form 4)4 - GRAIL, Inc. (0001699031) (Issuer)
- ANALYSTRBC Capital Mkts initiated coverage on GRAIL with a new price targetRBC Capital Mkts initiated coverage of GRAIL with a rating of Sector Perform and set a new price target of $84.00
- ANALYSTUBS resumed coverage on GRAIL with a new price targetUBS resumed coverage of GRAIL with a rating of Buy and set a new price target of $105.00
- PRGRAIL Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)SUNNYVALE, Calif., Sept. 3, 2026 /PRNewswire/ -- GRAIL, Inc. (NASDAQ:GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that it has granted equity awards in the form of restricted stock units ("RSUs") underlying an aggregate of 55,867 shares of GRAIL's common stock to 59 recently hired non-executive employees as an inducement material to their acceptance of employment with GRAIL. The employment inducement awards were granted under GRAIL's Inducement Equity Incentive Plan and related form of restricted stock award agreement in accordance with Nasdaq Listing Rule 5635(c)(4).
- INSIDERChief Executive Officer Ofman Joshua J. sold $425,098 worth of shares (5,000 units at $85.02), decreasing direct ownership by 1% to 397,271 units (SEC Form 4)4 - GRAIL, Inc. (0001699031) (Issuer)
- INSIDERChief Financial Officer Freidin Aaron sold $671,579 worth of shares (7,900 units at $85.01), decreasing direct ownership by 3% to 253,083 units (SEC Form 4)4 - GRAIL, Inc. (0001699031) (Issuer)
- PRGRAIL to Present at Morgan Stanley's 24th Annual Global Healthcare ConferenceMENLO PARK, Calif., Aug. 31, 2026 /PRNewswire/ -- GRAIL, Inc. (NASDAQ:GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that company management will present at the Morgan Stanley 24th Annual Global Healthcare Conference in New York on Monday, Sep. 14 at 11:30 a.m. ET. A live and replay webcast may be accessed in the investor relations section of GRAIL's website at investors.grail.com. The webcast will be archived and available for reply for at least 30 days after the event.About GRAILGRAIL is a healthcare company whose mission is to detect cancer early, when it can be cur
- SECAmendment: SEC Form SCHEDULE 13G/A filed by GRAIL Inc.SCHEDULE 13G/A - GRAIL, Inc. (0001699031) (Subject)
- PRGRAIL Announces FDA Advisory Committee Meeting to Review Premarket Approval Application for the Galleri® Multi-Cancer Early Detection TestMENLO PARK, Calif., Aug. 7, 2026 /PRNewswire/ -- GRAIL, Inc. (NASDAQ:GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that the U.S. Food and Drug Administration's (FDA) Molecular and Clinical Genetics Panel of the Medical Devices Advisory Committee is scheduled to meet on Sept. 23, 2026 to review the Premarket Approval (PMA) application for the Galleri® multi-cancer early detection (MCED) blood test. The Galleri test is designed to detect cancer-specific methylation patterns shared by many types of cancer before symptoms appear, including cancers that do not have recommen
- SECSEC Form SCHEDULE 13G filed by GRAIL Inc.SCHEDULE 13G - GRAIL, Inc. (0001699031) (Subject)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by GRAIL Inc.SCHEDULE 13G/A - GRAIL, Inc. (0001699031) (Subject)
- SECSEC Form 10-Q filed by GRAIL Inc.10-Q - GRAIL, Inc. (0001699031) (Filer)
- SECGRAIL Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - GRAIL, Inc. (0001699031) (Filer)
- PRGRAIL Reports Second Quarter 2026 Financial ResultsQ2 Galleri® Test Volume Increased 35% to More Than 61,000 Year-Over-Year, and Galleri Revenue Grew 24% to $42.6 Million Galleri Test Volume and Revenue are up 42% and 30% Year-Over-Year, Respectively, for the First Half of the YearNHS-Galleri and PATHFINDER 2 Study Results Presented at 2026 ASCO Annual Meeting Demonstrated Consistent Strong Performance and Clinical Utility for Galleri Completed $110 Million Equity Financing With Samsung MENLO PARK, Calif., Aug. 5, 2026 /PRNewswire/ -- GRAIL, Inc. (NASDAQ:GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today reported business and financial results for the second quarter of 2026.
- PRGRAIL to Present at the Canaccord Genuity 46th Annual Growth ConferenceMENLO PARK, Calif., July 30, 2026 /PRNewswire/ -- GRAIL, Inc. (NASDAQ:GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that company management will present at the Canaccord Genuity 46th Annual Growth Conference in Boston on Tuesday, Aug. 11 at 10:00 a.m. ET. Live and replay webcasts may be accessed in the investor relations section of GRAIL's website at investors.grail.com. The webcast will be archived and available for reply for at least 30 days after the event.About GRAILGRAIL is a healthcare company whose mission is to detect cancer early, when it can be cured. GRAIL
- PRGRAIL to Announce Second Quarter 2026 Financial ResultsMENLO PARK, Calif., July 29, 2026 /PRNewswire/ -- GRAIL, Inc. (NASDAQ:GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, announced today that it will issue financial results for the second quarter 2026 following the close of market on Wednesday, Aug. 5, 2026. Following the release, company management will host a webcast and conference call at 1:30 p.m. PT / 4:30 p.m. ET to discuss results and business progress. Second Quarter 2026 Webcast and Conference Call DetailsA link to the live webcast and recorded replay will be available at the investor relations section of GRAIL's website at inves
GRAL FAQ
5 questionsWhere does GRAL stock trade?
GRAIL Inc. (GRAL) is listed on NASDAQ.What sector and industry is GRAL in?
GRAIL Inc. operates in the Health Care sector, Medical Specialities industry.What are analysts saying about GRAL?
GRAIL Inc. has had 8 recent analyst actions on file. The most recent action was from RBC Capital Mkts: Sector Perform on 2026-09-17.What companies are similar to GRAL?
Notable peers in the same industry include UNH (UnitedHealth Group Incorporated), ANTM (Anthem Inc.), ELV (Elevance Health Inc.), CI (The Cigna Group), NTRA (Natera Inc.). Compare GRAL side-by-side with any of them on Quantisnow.How can I track GRAL on Quantisnow?
Quantisnow aggregates GRAIL Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow GRAL to receive live email and push alerts on every new disclosure.